The rapid development of the COVID-19 mRNA vaccines has demonstrated the tremendous potential of nucleic acid therapeutics. In this talk, Roy van der Meel will highlight how nanotechnology is enabling next generation RNA therapeutics for therapeutic gene silencing, expression, and editing.
Roy is appointed Assistant Professor at the TU/e’s Biomedical Engineering department where he heads the Precision Medicine group under direction of professor Willem Mulder. His research focuses on establishing platform nanotechnology for delivering nucleic acids to specific immune cells and therapeutically regulating the immune response in a highly precise manner.
Missed this edition? Don’t worry, we’ve got your back. Rewatch the edition here: